<DOC>
	<DOCNO>NCT02293096</DOCNO>
	<brief_summary>The investigator prospectively follow population patient uncontrolled high blood pressure begin metoprolol succinate therapy determine drug effect observational clinical trial . The investigator determine individual 's genotype CYP2D6 Adrenoceptor Beta 1 ( ADRB1 ) . Metabolomic marker identify determine specific metabolite associate drug response . The investigator ' overall objective determine genetics predict metoprolol succinate response well clinical factor age , race , body mass index , dose , medication co-ingestion .</brief_summary>
	<brief_title>Pharmacogenetic Prediction Metoprolol Effectiveness</brief_title>
	<detailed_description />
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>1 . Subjects age &gt; 30 year &lt; 80 year 2 . Subjects diagnosis uncontrolled essential hypertension . 1. end stage liver disease , 2. end stage renal disease , 3. pregnant female , 4 . American Society Anesthesiologists ( ASA ) classification &gt; 3 , 5. ward state , prisoner , 6. decisionally challenge , 7 . HR &lt; 60 bpm , 8 . AV block &gt; 240 msec , 9. active reactive airway disease , 10. illicit drug abuse precede 30 day , 11. hypersensitivity metoprolol derivatives 12. severe peripheral arterial circulatory disorder . Subjects screen physical exam perform Dr. Monte prior enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Genotype</keyword>
	<keyword>CYP2D6</keyword>
	<keyword>ADRB1</keyword>
</DOC>